Corcept Therapeutics (CORT) Interest Coverage Ratio (2010 - 2017)
Corcept Therapeutics (CORT) posted Interest Coverage Ratio of 3.73 for Q2 2026, up 186.36% sequentially from 4.32 in Q1 2026, and up 13.49% YoY from 3.29 in Q2 2025.
Powered by 
Analysis
Corcept Therapeutics (CORT) Interest Coverage Ratio (2010 - 2017) Analysis & Trends
Corcept Therapeutics has reported Interest Coverage Ratio for 17 years, with the latest figure at 3.73 in Q2 2026.
- Quarterly Interest Coverage Ratio rose 13.49% year-over-year to 3.73 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.58 (down 95.39% YoY) and the FY2025 annual result came in at 2.14, down 72.71% from the prior year.
- Interest Coverage Ratio grew to 3.73 in Q2 2026 per CORT's latest filing, from 4.32 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 2243.5 in Q4 2025 and troughed at 4.32 in Q1 2026.
- A 5-year average of 130.47 and a median of 3.6 in 2026 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2025 and 2026: Interest Coverage Ratio jumped 154961.0% in 2025, then tumbled 1173.11% in 2026.
- Over 5 years, Interest Coverage Ratio stood at 9.93 in 2022, then soared by 33.34% to 13.25 in 2023, then tumbled by 89.08% to 1.45 in 2024, then surged by 154961.0% to 2243.5 in 2025, then plunged by 99.83% to 3.73 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 3.73, 4.32, and 2243.5 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Corcept Therapeutics | 11.76 Bn | 11.46 Bn | 252.09 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | 130.56 |
| Mar 31, 2017 | 21.07 |
| Dec 31, 2016 | 12.21 |
| Sep 30, 2016 | 6.31 |
| Jun 30, 2016 | 2.84 |
| Mar 31, 2016 | 0.97 |
| Dec 31, 2015 | 2.39 |
| Sep 30, 2015 | 0.15 |
| Jun 30, 2015 | -1.51 |
| Mar 31, 2015 | -5.04 |
| Dec 31, 2014 | -3.76 |
| Sep 30, 2014 | -5.65 |
| Jun 30, 2014 | -6.78 |
| Mar 31, 2014 | -12.01 |
| Dec 31, 2013 | -9.17 |
| Sep 30, 2013 | -8.35 |
| Jun 30, 2013 | -9.68 |
| Mar 31, 2013 | -9.59 |
| Dec 31, 2012 | -8.72 |
| Sep 30, 2012 | -12.33 |